Hims & Hers Health Rises 1.34% on $1.22 Billion Volume Hits 46th in Trading Activity Amid Legal and Regulatory Turmoil

Hims & Hers Health (HIMS) closed August 21, 2025, with a 1.34% price increase and a trading volume of $1.22 billion, ranking 46th in market activity. The stock's recent trajectory has been shaped by strategic shifts in its partnership landscape and regulatory scrutiny.

The termination of Hims' collaboration with Novo Nordisk in August 2025 marked a pivotal moment. Novo redirected its compounded GLP-1 weight-loss drug initiatives to GoodRx, a move that immediately heightened legal exposure for Hims and intensified competition in telehealth weight management services. The partnership dissolution underscores evolving risks around compounded drug compliance and market access, which now dominate the company's short-term growth calculus.

Regulatory compliance has become a critical operational focus as active lawsuits over compounded drug promotion remain unresolved. This development amplifies the importance of Hims' ability to pivot toward non-GLP-1 product categories while maintaining subscriber retention. Analysts emphasize that execution on alternative offerings will be crucial to balancing revenue stability against intensified regulatory oversight.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but was subject to market fluctuations. It performed best in June 2023, with returns of 7.02%, and worst in September 2022, with a return of -4.20%. Overall, the strategy provided modest capital appreciation with significant volatility.